# Epirium Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epirium-bio

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.epirium.com
- Total disclosed funding: $85M
- Latest round: Series A (Dec 18, 2019)
- Investors on record: 6

## About

Epirium Bio, Inc. is a biotechnology firm focused on developing innovative therapeutics for neuromuscular diseases. The company aims to address significant unmet medical needs with its unique small molecules enhancing mitochondrial function and muscle health.Founded in 2008, Epirium Bio, Inc. operates out of San Diego, US. The company specializes in therapeutics aimed at neuromuscular diseases, with its primary candidate, EPM-01, targeting Becker muscular dystrophy. Jon Taub serves as both CEO and founder. In its history, Epirium Bio has raised USD 85 mn in Series A funding from investors including ARCH Venture Partners and Longitude Capital, which took place on December 18, 2019. The firm has engaged in a total of three funding deals.Epirium Bio specializes in the development of innovative therapeutics aimed at addressing significant unmet medical needs in neuromuscular diseases. The company's primary product candidate, EPM-01, is an orally bioavailable synthetic compound specifically targeting Becker muscular dystrophy, which has shown proof-of-concept in both preclinical and clinical studies for mitochondrial dysfunction. Epirium Bio’s proprietary platform revolves around its unique small molecules that enhance mitochondrial function and muscle health, with applications extending to conditions such as sarcopenia and spinal muscular atrophy. The company’s research and products are directed towards healthcare providers and institutions primarily located in the United States, with aspirations to expand into other developed markets that focus on muscle degenerative diseases. As Epirium continues to advance its therapeutic pipeline, it aims to reach a diverse patient population in need of effective treatment options for these debilitating conditions.Epirium Bio's revenue model is centered on the development and commercialization of its therapeutic candidates, particularly EPM-01. The company engages in strategic partnerships and collaborations with healthcare entities, which may involve milestone payments and royalties upon successful product development and commercialization. Transactions typically occur through agreements with pharmaceutical companies and research institutions, focusing on the advanced clinical trials needed to bring its products to market. As the company progresses through its clinical development phases, particularly with ongoing trials for EPM-01, the financial structure may incorporate grant funding from nonprofit organizations dedicated to muscular dystrophy research, which can support operational costs and enhance research capabilities. The revenue generated from these activities is anticipated to derive predominantly from licensing agreements and the eventual sales of its proprietary therapeutics upon successful regulatory approvals.Epirium Bio plans to utilize the USD 85 mn raised in its Series A funding to advance its therapeutic pipeline, particularly with the ongoing trials for EPM-01. The company aims to expand its reach into new markets, specifically targeting developed regions with high needs for therapies related to muscle degenerative diseases. As these initiatives progress, Epirium Bio is focused on introducing new products designed to enhance patient care and address significant gaps in treatment options. The strategic partnerships formed will also strengthen their market entry and product development efforts.

## Funding rounds

- Series A, Dec 18, 2019, $85M — Adams Street Partners, ARCH Venture Partners, Longitude Capital, BlueBird Venture, The Longevity Fund, Vertex Ventures HC

## Investors

- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series A
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A
- BlueBird Venture — Series A
- The Longevity Fund (https://capitalatlas.ai/funds/the-longevity-fund) — Series A
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series A